Program Overview

Participants will benefit by:  

• Strategic Business Matching: Facilitating tailored B2B and B2G meetings with pharmaceutical companies, biotech companies, hospitals, and key stakeholders to support market diversification for Australia’s biotech and health sectors across China.
• Branded Australian Pavilion at DIA China: The DIA 2025 attracted more than 5,000 life cycle drug development professionals from NMC & local pharma companies, clinical study sites and CROs/CDMOs of over 30 countries and regions, and over 300 exhibitors globally. 

• Explore West China: Delivering an outreach program to Chengdu, an emerging biotech and medtech hub in China that hosts Cochlear's overseas R&D and manufacturing facility and Novotech's second Global Service Centre. It has also nurtured China's top-ranking research hospital, West China Hospital, and the West China-Marshall Research Centre for Infectious Diseases. 

Draft program

*Please note that this is a draft program and subject to change.*